Opioids

Researchers from the University of Massachusetts and Colorado State University released a new study on the impact recreational marijuana laws have on opioid-induced deaths. The study links the availability of adult-use cannabis to a decrease in deaths by opioid overdose. The study found that...

Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley analyst David Risinger made the following changes to his pharma stock coverage: Endo...

A study published this month in the Proceedings of the National Academy of Sciences of the United States of America is pushing back on the line of thinking that medical marijuana could lower the number of opioid overdoses. The Findings States with medical marijuana laws showed slower increases in...

Russian parliament has passed a law that would allow the cultivation of psychoactive plants, including cannabis and opium poppies, for pharmaceutical purposes. The move aims to cover the country's needs for painkillers amid sanctions. What Happened In a document from the Russian government...

Insys Therapeutics Inc (NASDAQ: INSY) Chairman Steven Meyer and board member Pierre Lapalme will resign "upon the execution of the agreements relating to the settlement with the U.S. Department of Justice," according to Reuters. Insys Therapeutics has agreed to pay $225 million and plead...

With Johnson & Johnson (NYSE: JNJ) facing off against the state of Oklahoma this week over its potential responsibility for the opioid crisis in that state, BMO Capital Markets issued a report Thursday on the company's thinking as it heads to court. The Analyst Joanne Wuensch...

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares have been under pressure since mid-May, when it was accused along with other generic companies for inflating the prices of generic drugs. The Israeli drugmaker announced an $85-million settlement agreement Tuesday with the state of...

Opioid drugmaker Insys Therapeutics Inc (NASDAQ: INSY) may soon go bust, the company suggested in the first-quarter earnings report it released Friday after the close. Following Insys' fourth-quarter print in March, analysts were largely bullish on the company, premising their optimism on...

By Eve Ripley, via Medical Marijuana Inc. News. It’s been an exciting 12-months for cannabis research. Check out these top 10 marijuana studies published within the last year. Every year, researchers discover more about marijuana and its effects. Celebrate 4/20 this year by learning what we...

The Street will gain access this week to an investment in the only opioid marketed in the U.S. and Europe without being classified as a controlled substance. The IPO Trevi Therapeutics, Inc. will issue nearly 4.7 million shares on the Nasdaq under ticker TRVI, according to the firm’s S-1...

Former Detroit Lions players Calvin Johnson and Rob Sims joined Benzinga CEO Jason Raznick onstage Wednesday at the Cannabis Capital Conference in Toronto. Johnson and Sims discussed industry activity in Michigan, their experiences in the NFL and ending the stigma around cannabis in specific...

Vireo Health International (OTC:VREOF), a science-focused multistate cannabis operator, is expanding into Massachusetts through the acquisition of Mayflower Botanicals, one of the state’s registered marijuana dispensaries. Vireo operates in nine states, but Massachusetts will be the...

Insys Therapeutics (NASDAQ: INSY) shares were crashing Wednesday after the company disclosed in its annual filing that the auditor's opinion on its audited financial statements include a paragraph stating concerns about the company's ability to continue. The stock was halted on a...

Cannabis stocks have been red-hot so far in 2019, and Piper Jaffray analyst Michael Lavery said Monday that the outlook for medical cannabis is brighter than ever. Lavery recently met with a pain specialist to determine how much of an impact medical marijuana could have on the business of pain...

Privately held Purdue Pharma, which has the dubious distinction of being a party to the opioid crisis in the U.S., is reportedly considering filing for Chapter 11 bankruptcy as it faces a slew of lawsuits tied to the opioid OxyContin, according to reports from Reuters and the Wall Street...